Amiloride (MK-870): Mechanism, Benchmarks, and Limits in Sodium Channel Research

Executive Summary: Amiloride (MK-870) is a small-molecule inhibitor targeting epithelial sodium channels (ENaC) and urokinase-type plasminogen activator receptors (uPAR) [APExBIO]. It blocks PC2 channels and modulates sodium-ion transport in epithelial tissues [Ref1]. Experimental evidence shows that Amiloride does not inhibit clathrin-mediated endocytosis of type III grass carp reovirus, clarifying its specificity [Wang et al., 2018]. The compound is widely used in cystic fibrosis and hypertension research for dissecting ENaC and uPAR pathways [Ref2]. Proper storage at -20°C is essential for maintaining reagent stability [APExBIO].

Biological Rationale

Amiloride (MK-870) is a pyrazine derivative with the chemical formula C6H8ClN7O and molecular weight 229.63 Da [APExBIO]. It selectively inhibits epithelial sodium channels (ENaC) in the apical membrane of epithelial cells, reducing sodium reabsorption in renal and airway tissues [Ref3]. This mechanism underpins its use as a reference compound in studies of sodium transport, fluid balance, and hypertension. Amiloride also binds to urokinase-type plasminogen activator receptors (uPAR), modulating cellular signaling. Its effects on PC2 channels contribute to investigations of ion channelopathies and cellular endocytosis [Ref4]. The compound is not used therapeutically in this context; all applications are research-focused.

Mechanism of Action of Amiloride (MK-870)

Amiloride (MK-870) acts as a competitive, reversible blocker at the extracellular face of ENaC, reducing sodium influx through these channels. This inhibits downstream signaling related to sodium and water transport in epithelial tissues. The compound also interacts with the urokinase receptor (uPAR), disrupting uPA-mediated cell signaling and migration. Amiloride blocks PC2 (polycystin-2) channels, affecting calcium and sodium fluxes within the cell. Its rapid, reversible mode of action enables precise temporal control in cell-based assays. Amiloride's selectivity profile distinguishes it from broader-spectrum ion channel inhibitors.

Evidence & Benchmarks

• Amiloride (MK-870) does not inhibit clathrin-mediated endocytosis of type III grass carp reovirus in CIK cells, as shown by lack of effect on viral entry and replication (Wang et al. 2018, https://doi.org/10.1186/s12985-018-0993-8).
• Amiloride's IC50 for ENaC is typically 0.1–10 μM, depending on cell type and assay conditions (https://mk-0822.com/index.php?g=Wap&m=Article&a=detail&id=15371).
• In cystic fibrosis models, Amiloride reduces sodium hyperabsorption in airway epithelial cells (https://ionomycin-calcium-salt.com/index.php?g=Wap&m=Article&a=detail&id=98).
• Amiloride is not effective against dynamin-dependent endocytosis; ammonium chloride and dynasore are required for inhibition in this context (Wang et al. 2018, https://doi.org/10.1186/s12985-018-0993-8).
• The compound is unstable in solution for long-term storage; it should be freshly prepared and kept at -20°C as a solid (APExBIO).

Applications, Limits & Misconceptions

Amiloride (MK-870) is primarily used in basic research to probe ENaC and uPAR function, as well as to dissect sodium transport mechanisms in epithelial tissues. Common applications include:

• Dissecting the contribution of ENaC to sodium absorption in kidney and airway models.
• Studying uPAR-mediated signaling in cell migration and cancer models.
• Serving as a negative control for endocytosis pathways not involving ENaC/uPAR.
• Exploring workflows in cystic fibrosis and hypertension research involving sodium channel dysregulation.

Common Pitfalls or Misconceptions

• Amiloride (MK-870) does not block clathrin-mediated or dynamin-dependent endocytosis of type III grass carp reovirus (Wang et al. 2018, DOI).
• It is ineffective as an antiviral agent in models where viral entry depends on clathrin or dynamin.
• Amiloride does not inhibit all sodium channels; it is selective for ENaC and certain PC2 channels.
• Long-term storage of Amiloride solutions (>24h) at room temperature or 4°C leads to loss of activity (APExBIO).
• Results obtained in non-epithelial models may not extrapolate to ENaC-mediated processes.

Workflow Integration & Parameters

APExBIO supplies Amiloride (MK-870) as a solid (SKU BA2768), with recommended storage at -20°C to preserve stability. Solutions should be freshly prepared in DMSO or aqueous buffers and used promptly. For endocytosis or ion channel assays, typical working concentrations range from 0.1 to 100 μM, though optimization by titration is advised. Shipping is under Blue Ice for small molecules; Dry Ice is used for nucleotides. The product is for research use only—not for diagnostic or medical purposes. See the Amiloride (MK-870) product page for batch-specific data.

This article updates and clarifies the mechanistic boundaries discussed in "Amiloride (MK-870): Redefining ENaC and uPAR Inhibition" by directly benchmarking against viral endocytosis assays. For a systems biology perspective on sodium channel and uPAR interplay, see "A Systems Biology Lens on Sodium Channel Research"; this article provides updated, assay-specific evidence. For workflow design and troubleshooting, "Applied Workflows in Sodium Channel Research" focuses on experimental reproducibility, while the present article emphasizes inhibitor specificity and limitations.

Conclusion & Outlook

Amiloride (MK-870) from APExBIO is a rigorously characterized ENaC and uPAR inhibitor with well-defined mechanistic boundaries. It is not a universal endocytosis blocker, and its selectivity must be considered in experimental design. Reliable performance in sodium channel and receptor studies is supported by peer-reviewed benchmarks. Future research will further delineate its applications in disease models and systems biology frameworks.